Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation

Jonge, Maja J.A. de; Slingerland, Marije; Loos, Walter J.; Wiemer, Erik A.C.; Burger, Herman; Mathijssen, Ron H.J.; Kroep, Judith R.; Hollander, Margret A.G. den; Biessen, D. van der; Lam, Mei-Ho; Verweij, Jaap; Gelderblom, Hans

doi:10.1016/j.ejca.2010.07.015

Cited by 79 publications

(32 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the study, the drug was given as an i.v. infusion over one hour, every three weeks in advanced breast cancer patients (de Jonge et al 2010). Unfortunately, the study ended early as the results demonstrated no benefit in the dose or toxicity profile when compared with normal cisplatin.…”

Section: Liplacismentioning

confidence: 99%

See 1 more Smart Citation

The state-of-play and future of platinum drugs

Apps

Choi

Wheate

2015

Endocrine-Related Cancer

233

142

View full text Add to dashboard Cite

The year 2015 marks the 50th anniversary since the discovery of the anticancer potential of cisplatin and it remains just as useful now as it did back then, especially for the treatment of some endocrine-related cancers like ovarian and testicular carcinomas. Since its discovery, five other platin drugs have received approval in various countries. While several new platin drugs are in preclinical development, in the last decade only two new platin drugs have entered clinical trials, LA-12 and dicycloplatin, reflecting a shift in research focus from new drug design to improved formulations of already approved platin drugs. These formulations include their encapsulation with macrocycles to slow and prevent their degradation by proteins and peptides; their attachment to nanoparticles to passively target solid tumours through the enhanced permeability and retention effect and their coordination to important nutrients, proteins, antibodies and aptamers for active tumour targeting. These formulation methods have all shown potential but none have yet yielded a new marketable medicine containing a platin drug. The reasons for this are problems of consistent drug loading, controlling the location and timing of drug release and the inherent toxicity of some of the drug delivery vehicles. In addition to drug delivery, functional genomics is now playing an increasing role in predicting patients' responses to platin chemotherapy and their likelihood of experiencing severe side effects.

show abstract

Section: Liplacismentioning

confidence: 99%

“…Unfortunately, the study ended early as the results demonstrated no benefit in the dose or toxicity profile when compared with normal cisplatin. The study concluded that LaPlaCis needed reformulation if it was to be effective (de Jonge et al 2010).…”

Section: Liplacismentioning

confidence: 99%

The state-of-play and future of platinum drugs

Apps

Choi

Wheate

2015

Endocrine-Related Cancer

233

142

View full text Add to dashboard Cite

show abstract

“…NOVEL APPROACHES FOR CANCER THERAPIES was stopped after a Phase I study when it was found that LiPlaCis did not prevent the renal toxicity of cisplatin and the incidence of acute infusion reactions was relatively high in this trial. 26 Finally, a liposomal formulation of vinorelbine (NanoVNB ® ) 27 is in clinical development (Phase I/II trials). As we do not want to replicate the earlier reviews by Chang and Yen, 19 Sen and Mandal, 20 Slingeland et al, 21 and Koudelka and Turanek, 22 we limit our examples to these few.…”

Section: Liposomes For the Delivery Of Chemotherapeuticsmentioning

confidence: 99%

Recent Advances and Trends in the Brain Delivery of Small Molecule Based Cancer Therapies

Gladdines

Visser

Boer

et al. 2015

Novel Approaches and Strategies for Biologics, Vaccines and Cancer Therapies

View full text Add to dashboard Cite

“…There are over 1000 clinical trials containing the terms "liposome" and "cancer," either completed or active, according to The National Institutes of Health's (NIH) web-based database, ClinicalTrials.gov and the EU Clinical Trial Register. There are several ongoing clinical trials investigating the efficiency of liposomal cisplatin, NDDP (cisplatin analog), paclitaxel, mitoxantrone, irinotecan, SN38 (the active metabolite of irinotecan), topotecan, lurtotecan, a camptothecin analog, vinorelbine, annamycin, docetaxel, DOX, and vincristine [83][84][85][86][87]. The association of chemotherapeutic drugs is a frequently used strategy in chemotherapy.…”

Section: Clinical Experience With Liposomes For Cancer Chemotherapymentioning

confidence: 99%

Liposomal Nanoformulations as Current Tumor-Targeting Approach to Cancer Therapy

Porfire¹,

Achim²,

Tefas³

et al. 2017

Liposomes

View full text Add to dashboard Cite

The liposomes present great potential for applications in targeted delivery of chemotherapeutics in the treatment of cancer. The use of liposomal drug carriers as vehicles for targeting of chemotherapeutic agents to tumor tissues is based on their advantages over other dosage forms, represented by their low systemic toxicity, their bioavailability, and their possibility to enhance the solubility of different chemotherapeutic agents, due to the ability to encapsulate both hydrophilic and lipophilic drugs. They enhance the therapeutic index of anticancer drugs by increasing the drug concentration in tumor cells through tumor targeting. The available approaches used for tumor targeting using liposomes are passive targeting, active targeting, and triggered drug release. The most advanced targeting strategies proposed for cancer treatment are the development of multifunctional liposomes, having combined targeting mechanism. In this chapter, the tumor-targeting mechanisms are described in detail as well as the possibilities to design the targeted liposomal nanocarrier in order to reach the desired target in the body and minimizing the off-target effects. Moreover, the current status of preclinical and clinical evaluation is highlighted.

show abstract

Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation

Cited by 79 publications

References 18 publications

The state-of-play and future of platinum drugs

The state-of-play and future of platinum drugs

Recent Advances and Trends in the Brain Delivery of Small Molecule Based Cancer Therapies

Liposomal Nanoformulations as Current Tumor-Targeting Approach to Cancer Therapy

Contact Info

Product

Resources

About